Wolfe Research Upgrades Immunovant to Outperform with $50 Target
Wolfe Research upgrades Immunovant stock, citing higher valuation support, declining short interest, and positive catalysts ahead in 2026.
Wolfe Research upgrades Immunovant stock, citing higher valuation support, declining short interest, and positive catalysts ahead in 2026.
argenx discontinues Phase 3 trials of efgartigimod SC for thyroid eye disease after independent review finds treatment unlikely to meet goals. Safety profile remained favorable.